528 related articles for article (PubMed ID: 27034234)
1. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
Chester C; Ambulkar S; Kohrt HE
Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of cancer with 4-1BB.
Vinay DS; Kwon BS
Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
[TBL] [Abstract][Full Text] [Related]
4. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
5. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
Compte M; Harwood SL; Muñoz IG; Navarro R; Zonca M; Perez-Chacon G; Erce-Llamazares A; Merino N; Tapia-Galisteo A; Cuesta AM; Mikkelsen K; Caleiras E; Nuñez-Prado N; Aznar MA; Lykkemark S; Martínez-Torrecuadrada J; Melero I; Blanco FJ; Bernardino de la Serna J; Zapata JM; Sanz L; Alvarez-Vallina L
Nat Commun; 2018 Nov; 9(1):4809. PubMed ID: 30442944
[TBL] [Abstract][Full Text] [Related]
6. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
7. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
8. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
Stoll A; Bruns H; Fuchs M; Völkl S; Nimmerjahn F; Kunz M; Peipp M; Mackensen A; Mougiakakos D
Leukemia; 2021 Dec; 35(12):3482-3496. PubMed ID: 34021248
[TBL] [Abstract][Full Text] [Related]
9. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
10. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.
Li Q; Iuchi T; Jure-Kunkel MN; Chang AE
Int J Biol Sci; 2007 Nov; 3(7):455-62. PubMed ID: 18071585
[TBL] [Abstract][Full Text] [Related]
12. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
[TBL] [Abstract][Full Text] [Related]
13. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
[TBL] [Abstract][Full Text] [Related]
14. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
15. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
[TBL] [Abstract][Full Text] [Related]
16. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
[TBL] [Abstract][Full Text] [Related]
17. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
19. Targeting 4-1BB for tumor immunotherapy from bench to bedside.
Wang YT; Ji WD; Jiao HM; Lu A; Chen KF; Liu QB
Front Immunol; 2022; 13():975926. PubMed ID: 36189243
[TBL] [Abstract][Full Text] [Related]
20. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
